Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma - A comparison of doxorubicin and pirarubicin: A randomized phase II study

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 2, 2004, Pages 107-113

  Tsurumi, Hisashi ^a   Yamada, Toshiki ^a   Sawada, Michio ^a   Kasahara, Senji ^b   Kanemura, Nobuhiro ^a   Kojima, Yasushi ^a   Fukuno, Kenji ^c   Hara, Takeshi ^a,d   Saio, Masanao ^a   Takahashi, Takeshi ^e   Oyama, Masami ^b   Ozawa, Keiya ^d   Takami, Tsuyoshi ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c Takayama Red Cross Hospital   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e Gifu Municipal Hospital   (Japan)

Author keywords

Aggressive non Hodgkin's lymphoma; Biweekly CHOP; Doxorubicin; Pirarubicin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHYLPREDNISOLONE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART FAILURE; HEMATURIA; HUMAN; INFECTION; KIDNEY DISEASE; LIVER DYSFUNCTION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZATION; RESPIRATORY FAILURE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISOLONE; PREDNISONE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 12144285694     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0508-9     Document Type: Article

References (28)

1. Aoki S, Tsukada N, Nomoto N, Maruyama S, Takahashi M. Moriyama Y, Shibata A, Aizawa Y (1998) Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res 17:465-470
2. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860-1861
3. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Kippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253
4. Cox DR (1972) Regression models and life-tables (with discussions). J Roy Stat Soc (Series B) 34:187-220
5. DeVita VT Jr, Hubbard SM, Longo DL (1987) The chemotherapy of lymphomas: looking back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47:5810-5824
6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006
7. Gianni AS, Bregni M, Siena S, Brambilla C, Nicola MD, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336:1290-1297
8. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F for the Group d'Etude des Lymphomes de I'Adulte (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 15:1131-1137
9. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P, Reyes F (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Group d'Etude des Lymphomes de I'Adulte Study. J Clin Oncol 18:3025-3030
10. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization classification of tumors, pathology and genetics. Tumors of haematopoietic and lymphoid tissues. IARC Lyon, pp 109-236
11. Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
12. Kitamura K, Takaku F (1990) Pirarubicin, a novel derivative of doxorubicin, in THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 13[Suppl]:S15-S19
13. Kwak LW, Halpern J, Olshen RA, Horning SJ (1990) Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 8:963-977
14. Miller AA, Salewski E (1994) Prospects for pirarubicin. Med Pediatr Oncol 22:261-268
15. Niitsu N, Umeda M (1997) THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study. Leukemia 11:1817-1820
16. Niitsu N, Umeda M (1998) Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin, and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate and high grade non-Hodgkin's lymphoma. Leukemia 12:1457-1460
17. Niitsu N, Umeda M (1999) Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol 63:337-344
18. Niitsu N, Okamoto M, Kuraishi Y, Nakamura S, Kodama F, Hirano M, The Adult Lymphoma Treatment Study Group (2000) CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. Eur J Haematol 65:188-194
19. Santoro A, Balzarotti M, Tondini C, Zanini M, Giardini R, Latteri F, Rampinelli I, Bufalino R (1999) Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 10:519-525
20. Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354-361
21. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN (1995) High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 13:2916-2923
22. Takagi T, Oguro M (1987) (2″-R)-4′-o- Tetrahydropyranyladriamycin, a new anthracyclin derivative; its effectiveness in lymphoid malignancies. Cancer Chemother Pharmacol 20:151-154
23. Takagi T, Sakai C, Oguro M (1990) Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEP-THP therapy) in the treatment of non-Hodgkin's lymphoma. Oncology 47:25-28
24. Tanosaki R, Okamoto S, Akatsuka N, Ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y (1994) Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 74:1939-1944
25. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994
26. The non-Hodgkin's lymphoma pathologic classification project (1982) National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135
27. Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T (1979) Tetrahydropyranyl derivatives of daunomycin and adriamycin. J Antibiot 32:1082-1084
28. Witzig TE, Camoriano JK, Schroeder G, Kurtin PJ, Habermann TM (1998) A phase I trial of high-dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma. Leukemia Lymphoma 28:307-314